{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-009042","form_type":"8-K","ticker":"CVM","cik":"0000725363","company_name":"CEL SCI CORP","filed_at":"2023-07-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.512513+00:00","generated_at":"2026-06-13T09:39:46.134855+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cel-SCI reports Multikine Phase 3 biomarker data: 20% 5-year OS benefit in low PD-L1 head & neck cancer patients","bullets":["Low PD-L1 subgroup (TPS<10) showed 20% absolute 5-year overall survival advantage for Multikine+SOC vs SOC alone (60% vs 40% alive).","PD-L1 low subgroup represents >70% of lower-risk patients; hazard ratio 0.68 for LR population all patients.","Data suggest potential to combine Multikine with checkpoint inhibitors like Keytruda or Opdivo for broader coverage.","Company filed patent for Multikine use in tumors with low PD-L1 expression.","Previously reported 14.1% absolute 5-year OS benefit in lower-risk ITT patients; now biomarker confirms effect."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-009042","json":"https://secwatch.observer/filing/0001654954-23-009042.json","markdown":"https://secwatch.observer/filing/0001654954-23-009042.md","text":"https://secwatch.observer/filing/0001654954-23-009042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/725363/000165495423009042/0001654954-23-009042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/725363/000165495423009042/cvm_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T09:39:46.134855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}